{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:55:50Z","timestamp":1787586950005,"version":"build-2736575974"},"reference-count":30,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T00:00:00Z","timestamp":1719187200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013327","name":"H. Lundbeck A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2024,7]]},"abstract":"Abstract<\/jats:title>\n \n Objective<\/jats:title>\n This post hoc analysis of the PREVAIL study explored the effectiveness of eptinezumab for up to 2\u2009years of open\u2010label treatment in the subgroup of patients with chronic migraine who had a confirmed diagnosis of medication\u2010overuse headache (MOH) at screening.<\/jats:p>\n <\/jats:sec>\n \n Background<\/jats:title>\n MOH is a disabling and costly secondary headache disorder characterized by increased headache frequency and\/or severity with increased acute headache medication use. Eptinezumab, an anti\u2013calcitonin gene\u2010related peptide monoclonal antibody, reduces headache frequency, severity, and associated disability and improves functioning and health\u2010related quality of life as a preventive migraine therapy; short\u2010term benefits in patients with concurrent MOH have also been reported.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Participants received up to eight quarterly intravenous infusions of eptinezumab 300\u2009mg in the phase 3, single\u2010arm, open\u2010label PREVAIL study. Safety and patient\u2010reported outcome measures (Migraine Disability Assessment [MIDAS], 6\u2010item Headache Impact Test [HIT\u20106], patient\u2010identified most bothersome symptom [PI\u2010MBS], Patient Global Impression of Change [PGIC], and 36\u2010item Short\u2010Form Health Survey [SF\u201036]) were conducted at predefined intervals. Patients were observed up to 20\u2009weeks after their last infusion (Week 104).<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 49\/128 (38.3%) patients enrolled in PREVAIL had an MOH diagnosis at screening. In the MOH subgroup, long\u2010term eptinezumab treatment was associated with reductions in headache frequency (43\/49 [87.8%] patients reported \u226550% reduction in MIDAS\u2010derived headache days at \u22651 visit), severity (2.2\u2010point reduction [on a 10\u2010point scale]), disability (mean MIDAS total score reduction of 51.9 points), and impact (mean HIT\u20106 total score reduction of 9.7 points) at Week 104. Most patients described a \u201cmuch improved\u201d or \u201cvery much improved\u201d status by Week 48 (PI\u2010MBS, 31\/46 [67.4%]) and Week 104 (PGIC, 31\/36 [86.1%]). Health\u2010related quality of life improvements in the SF\u201036 were also observed.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Eptinezumab preventive therapy in patients with chronic migraine showed benefits that extended to the subset of patients with concomitant MOH.<\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/head.14767","type":"journal-article","created":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T03:24:20Z","timestamp":1719199460000},"page":"738-749","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Long\u2010term effectiveness of eptinezumab in the treatment of patients with chronic migraine and medication\u2010overuse headache"],"prefix":"10.1111","volume":"64","author":[{"given":"Andrew","family":"Blumenfeld","sequence":"first","affiliation":[{"name":"The Los Angeles Headache Center Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kudrow","sequence":"additional","affiliation":[{"name":"The Los Angeles Headache Center Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"McAllister","sequence":"additional","affiliation":[{"name":"New England Institute for Neurology and Headache Stamford Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Line Pickering","family":"Boserup","sequence":"additional","affiliation":[{"name":"Department of Neurology H. Lundbeck A\/S Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Hirman","sequence":"additional","affiliation":[{"name":"Pacific Northwest Statistical Consulting Woodinville Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Cady","sequence":"additional","affiliation":[{"name":"RK Consults Ozark Missouri USA"},{"name":"Missouri State University Springfield Missouri USA"},{"name":"Axon Therapeutics San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,6,24]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s10194-018-0865-z","article-title":"Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study","volume":"19","author":"Schwedt TJ","year":"2018","journal-title":"J Headache Pain"},{"key":"e_1_2_13_3_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"The International Classification of Headache Disorders, 3rd edition","volume":"38","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2018","journal-title":"Cephalalgia"},{"key":"e_1_2_13_4_1","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","author":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators","year":"2018","journal-title":"Lancet"},{"key":"e_1_2_13_5_1","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/head.14056","article-title":"Headache characteristics and burden from chronic migraine with medication overuse headache: cross\u2010sectional observations from the medication overuse treatment strategy trial","volume":"61","author":"Schwedt TJ","year":"2021","journal-title":"Headache"},{"key":"e_1_2_13_6_1","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s40263-021-00818-9","article-title":"The evolution of medication overuse headache: history, pathophysiology and clinical update","volume":"35","author":"Sun\u2010Edelstein C","year":"2021","journal-title":"CNS Drugs"},{"key":"e_1_2_13_7_1","doi-asserted-by":"crossref","first-page":"5759","DOI":"10.1007\/s10072-022-06265-8","article-title":"Overview on effectiveness of erenumab, fremanezumab, and galcanezumab in reducing medication overuse headache in chronic migraine patients","volume":"43","author":"Curone M","year":"2022","journal-title":"Neurol Sci"},{"key":"e_1_2_13_8_1","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/0333102420905132","article-title":"Eptinezumab in episodic migraine: a randomized, double\u2010blind, placebo\u2010controlled study (PROMISE\u20101)","volume":"40","author":"Ashina M","year":"2020","journal-title":"Cephalalgia"},{"key":"e_1_2_13_9_1","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1016\/j.clinthera.2020.11.007","article-title":"Eptinezumab for the prevention of episodic migraine: sustained effect through 1 year of treatment in the PROMISE\u20101 study","volume":"42","author":"Smith TR","year":"2020","journal-title":"Clin Ther"},{"key":"e_1_2_13_10_1","doi-asserted-by":"crossref","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","article-title":"Efficacy and safety of eptinezumab in patients with chronic migraine. PROMISE\u20102","volume":"94","author":"Lipton RB","year":"2020","journal-title":"Neurology"},{"key":"e_1_2_13_11_1","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-020-01186-3","article-title":"Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24\u2009weeks of treatment in the phase 3 PROMISE\u20102 (prevention of migraine via intravenous ALD403 safety and efficacy\u20132) study","volume":"21","author":"Silberstein S","year":"2020","journal-title":"J Headache Pain"},{"key":"e_1_2_13_12_1","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1177\/0333102419858355","article-title":"Eptinezumab for prevention of chronic migraine: a randomized phase 2b clinical trial","volume":"39","author":"Dodick DW","year":"2019","journal-title":"Cephalalgia"},{"key":"e_1_2_13_13_1","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-021-02123-w","article-title":"Long\u2010term safety and tolerability of eptinezumab in patients with chronic migraine: a 2\u2010year, open\u2010label, phase 3 trial","volume":"21","author":"Kudrow D","year":"2021","journal-title":"BMC Neurol"},{"key":"e_1_2_13_14_1","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1111\/head.14206","article-title":"Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication\u2010overuse headache","volume":"61","author":"Marmura MJ","year":"2021","journal-title":"Headache"},{"key":"e_1_2_13_15_1","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1177\/03331024221089567","article-title":"Reduction in migraine\u2010associated burden after eptinezumab treatment in patients with chronic migraine","volume":"42","author":"McAllister P","year":"2022","journal-title":"Cephalalgia"},{"key":"e_1_2_13_16_1","first-page":"129","article-title":"Impact of baseline characteristics on the efficacy and safety of eptinezumab in patients with migraine: subgroup analyses of PROMISE\u20101 and PROMISE\u20102","volume":"61","author":"Martin VT","year":"2021","journal-title":"Headache"},{"key":"e_1_2_13_17_1","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-021-01227-5","article-title":"Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials","volume":"22","author":"Smith TR","year":"2021","journal-title":"J Headache Pain"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.762021.765822"},{"key":"e_1_2_13_19_1","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-022-02774-3","article-title":"Long\u2010term reductions in disease impact in patients with chronic migraine following preventive treatment with eptinezumab","volume":"22","author":"Blumenfeld A","year":"2022","journal-title":"BMC Neurol"},{"key":"e_1_2_13_20_1","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1177\/0333102413485658","article-title":"The International Classification of Headache Disorders, 3rd edition (beta version)","volume":"33","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2013","journal-title":"Cephalalgia"},{"key":"e_1_2_13_21_1","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1212\/WNL.56.suppl_1.S20","article-title":"Development and testing of the migraine disability assessment (MIDAS) questionnaire to assess headache\u2010related disability","volume":"56","author":"Stewart WF","year":"2001","journal-title":"Neurology"},{"key":"e_1_2_13_22_1","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/head.14153","article-title":"The American Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice","volume":"61","author":"Ailani J","year":"2021","journal-title":"Headache"},{"key":"e_1_2_13_23_1","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1023\/A:1026119331193","article-title":"A six\u2010item short\u2010form survey for measuring headache impact: the HIT\u20106","volume":"12","author":"Kosinski M","year":"2003","journal-title":"Qual Life Res"},{"key":"e_1_2_13_24_1","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/0333102410379890","article-title":"Validation of the Headache Impact Test (HIT\u20106) across episodic and chronic migraine","volume":"31","author":"Yang M","year":"2011","journal-title":"Cephalalgia"},{"key":"e_1_2_13_25_1","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/head.13701","article-title":"Content validity of HIT\u20106 as a measure of headache impact in people with migraine: a narrative review","volume":"60","author":"Houts CR","year":"2020","journal-title":"Headache"},{"key":"e_1_2_13_26_1","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/head.14036","article-title":"Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication\u2010overuse headache: subgroup analysis of PROMISE\u20102","volume":"61","author":"Diener HC","year":"2021","journal-title":"Headache"},{"key":"e_1_2_13_27_1","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/head.14120","article-title":"Patient\u2010identified most bothersome symptom in preventive migraine treatment with eptinezumab: a novel patient\u2010centered outcome","volume":"61","author":"Lipton RB","year":"2021","journal-title":"Headache"},{"key":"e_1_2_13_28_1","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1136\/jnnp-2021-327480","article-title":"Two\u2010year efficacy and safety of erenumab in participants with episodic migraine and 2\u20104 prior preventive treatment failures: results from the LIBERTY study","volume":"93","author":"Ferrari MD","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_2_13_29_1","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1114654","article-title":"Adding eptinezumab to brief patient education to treat chronic migraine and medication\u2010overuse headache: protocol for RESOLUTION\u2010A phase 4, multinational, randomized, double\u2010blind, placebo\u2010controlled study","volume":"14","author":"Jensen RH","year":"2023","journal-title":"Front Neurol"},{"key":"e_1_2_13_30_1","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-021-01328-1","article-title":"Anti\u2010CGRP monoclonal antibodies in chronic migraine with medication overuse: real\u2010life effectiveness and predictors of response at 6 months","volume":"22","author":"Caronna E","year":"2021","journal-title":"J Headache Pain"},{"key":"e_1_2_13_31_1","doi-asserted-by":"crossref","DOI":"10.1177\/03331024231156922","article-title":"Randomized controlled studies evaluating Topiramate, botulinum toxin type a, and mABs targeting CGRP in patients with chronic migraine and medication overuse headache: a systematic review and meta\u2010analysis","volume":"43","author":"Giri S","year":"2023","journal-title":"Cephalalgia"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14767","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T11:39:47Z","timestamp":1767613187000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.14767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,24]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1111\/head.14767"],"URL":"https:\/\/doi.org\/10.1111\/head.14767","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,24]]},"assertion":[{"value":"2023-10-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}